A Review of Fulvestrant in Breast Cancer
Mark R. Nathan, Peter Schmid
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.1007/s40487-017-0046-2 ↗
- Volume · Issue · Pages
- 5 · 1 · 17-29
- Publisher
- Springer International Publishing AG
- Article URL
- https://doi.org/10.1007/s40487-017-0046-2 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
08 May 2017
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 08 May 2017 | OpenAlex |
Keywords (as given): fulvestrant; estrogen receptor-positive breast cancer; selective estrogen receptor degrader; endocrine therapy; CDK4/6 inhibitors; palbociclib; ribociclib; PI3K/AKT/mTOR pathway; pictilisib; buparlisib; aromatase inhibitor resistance; ESR1 mutations; dose optimization; progression-free survival; combination therapy
HEC Status at Publication Not the journal's current status
HEC Status at PublicationNot conclusive
Historical status could not be conclusively determined.
- HEC status cannot be determined for this date: no HEC list is recorded as in effect on it.
Best available information, not a definitive status: HEC status cannot be determined for this date: no HEC list is recorded as in effect on it.
- Journal
- Oncology and Therapy
- Publication date used
- 08 May 2017 (OpenAlex publication date)
- Applicable HEC period
- None recorded for this date
- Category
- —
- Recognition status
- Unknown (NO_PERIOD_FOR_DATE)
- Source
- —
- Verification status
- Not available
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.